Cargando…

Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax

Detalles Bibliográficos
Autores principales:	Lima, Keli, Vicari, Hugo Passos, Carlos, Jorge Antonio Elias Godoy, da Silva, Jean Carlos Lipreri, Figueiredo-Pontes, Lorena Lobo de, Rego, Eduardo Magalhães, Machado-Neto, João Agostinho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885367/ https://www.ncbi.nlm.nih.gov/pubmed/33753045 http://dx.doi.org/10.1016/j.htct.2021.01.004

Ejemplares similares

P347: PHARMACOLOGICAL EZRIN INHIBITION REDUCES GROWTH, ADHESION, MIGRATION AND REGULATE GENE RELATED TO APOPTOSIS AND CELL CYCLE IN ACUTE LYMPHOBLASTIC LEUKAEMIA
por: Carlos Lipreri Da Silva, Jean, et al.
Publicado: (2023)

miRNAs as prognostic predictors in acute myeloid leukemia
por: Machado-Neto, João Agostinho, et al.
Publicado: (2023)

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms
por: Vicari, Hugo Passos, et al.
Publicado: (2022)

PB1826: CELLULAR AND MOLECULAR CHARACTERIZATION OF THE ANTINEOPLASTIC EFFECTS OF CEPHALOCHROMIN IN MODELS OF ACUTE MYELOID LEUKEMIA
por: Nascimento, Mariane Cristina Do, et al.
Publicado: (2023)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2020)

Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis
por: Champa, Devora, et al.
Publicado: (2016)

Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016)

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
por: Jiménez-Guerrero, Rocío, et al.
Publicado: (2018)

An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
por: Goard, Carolyn A, et al.
Publicado: (2013)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
por: Andersen, Petter I., et al.
Publicado: (2019)

Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells
por: Yu, Le, et al.
Publicado: (2016)

Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks Migration of Colorectal Cancer Cells
por: Koehler, Bruno Christian, et al.
Publicado: (2014)

OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis
por: Wroblewski, David, et al.
Publicado: (2013)

Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro
por: Varghese, Finny S., et al.
Publicado: (2021)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
por: Porto-Soares, Moysés Antonio, et al.
Publicado: (2020)

Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
por: Wei, Wei-Jun, et al.
Publicado: (2017)

Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity
por: Ehrenkaufer, Gretchen, et al.
Publicado: (2020)

Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
por: Takei, Hisashi, et al.
Publicado: (2021)

Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK
por: McCoy, F, et al.
Publicado: (2010)

Obatoclax Regulates the Proliferation and Fusion of Osteoclast Precursors through the Inhibition of ERK Activation by RANKL
por: Oh, Ju Hee, et al.
Publicado: (2015)

Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma
por: Espona-Fiedler, Margarita, et al.
Publicado: (2022)

Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy
por: Castillo Bautista, Cristina Marisol, et al.
Publicado: (2023)

The Multikinase Inhibitor AD80 Induces Mitotic Catastrophe and Autophagy in Pancreatic Cancer Cells
por: Lima, Keli, et al.
Publicado: (2023)

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
por: Su, Jung-Chen, et al.
Publicado: (2014)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
por: Eustace, Alex J, et al.
Publicado: (2018)

Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
por: Ramakrishnan, Vijay, et al.
Publicado: (2016)

Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms
por: Fernandes de Oliveira Costa, Amanda, et al.
Publicado: (2022)

Exploring redox vulnerabilities in JAK2(V617F)-positive cellular models
por: Lima, Keli, et al.
Publicado: (2021)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells
por: Or, Chi-Hung R., et al.
Publicado: (2016)

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
por: Li, Jingye, et al.
Publicado: (2021)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
por: Vereertbrugghen, Alexia, et al.
Publicado: (2021)

Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2018)

Response to NK cell content does not seem to influence engraftment in ex vivo T cell depleted haploidentical stem cell transplantation
por: Lobo de Figueiredo-Pontes, Lorena, et al.
Publicado: (2022)

Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells
por: Chukkapalli, Vineela, et al.
Publicado: (2018)

Data mining in acute myeloid leukemia: identification of disease biomarkers, prognostic factors, novel targets, and potential drugs
por: Machado-Neto, João Agostinho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8iil474bh2frpo848mr1ugl8e3